Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis

被引：34

作者：

Confavreux, C. B. ^{[2
]}

Chapurlat, R. D. ^{[1
,2
]}

机构：

[1] Hop Edouard Herriot, Serv Rhumatol, INSERM, U831, F-69003 Lyon, France

[2] Univ Lyon, Dept Rheumatol, INSERM, Hop Edouard Herriot,Hosp Civils Lyon,U831, F-69003 Lyon, France

来源：

OSTEOPOROSIS INTERNATIONAL | 2011年 / 22卷 / 04期

关键词：

Ankylosing spondylitis; Biologic therapies; Bone loss; Inflammatory joint diseases; Osteoporosis; Rheumatoid arthritis; TNF alpha blockers; Tocilizumab; INTERLEUKIN-1 RECEPTOR ANTAGONIST; NECROSIS-FACTOR-ALPHA; CARTILAGE TURNOVER MARKERS; CONTROLLED CLINICAL-TRIAL; T-CELL COSTIMULATION; X-RAY ABSORPTIOMETRY; MINERAL DENSITY; DOUBLE-BLIND; TNF-ALPHA; DISEASE-ACTIVITY;

D O I：

10.1007/s00198-010-1462-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Inflammatory joint diseases are responsible of chronic systemic inflammation, joint degradations, deformities, and altered quality of life. Patients suffering from chronic rheumatic diseases also present increased bone fragility and increased fracture risk. Registration of biologic therapies has deeply modified care in rheumatic diseases, especially in rheumatoid arthritis and ankylosing spondylitis. The available biologics are the anti proinflammatory cytokine therapies (TNF alpha blockers, anakinra and tocilizumab) and the biologics active on T cell activation (abatacept and rituximab). These drugs succeeded in blocking disease activity and joint degradation. They are also able to stop systemic bone loss among patients with inflammatory rheumatic diseases. In this review, we present the current understanding of the inflammatory-induced bone loss and the skeletal effects of biologic therapies in inflammatory joint diseases.

引用

页码：1023 / 1036

页数：14

共 135 条

[1] Cytokines and bone loss in a 5-year longitudinal study - Hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: The Danish Osteoporosis Prevention Study [J].

Abrahamsen, B ;

Bonnevie-Nielsen, V ;

Ebbesen, EN ;

Gram, J ;

Beck-Nielsen, H .

JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (08) :1545-1554

[2] CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris [J].

Abrams, JR ;

Lebwohl, MG ;

Guzzo, CA ;

Jegasothy, BV ;

Goldfarb, MT ;

Goffe, BS ;

Menter, A ;

Lowe, NJ ;

Krueger, G ;

Brown, MJ ;

Weiner, RS ;

Birkhofer, MJ ;

Warner, GL ;

Berry, KK ;

Linsley, PS ;

Krueger, JG ;

Ochs, HD ;

Kelley, SL ;

Kang, SW .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1243-1252

[3] Detailed analyses of periarticular osteoporosis in rheumatoid arthritis [J].

Alenfeld, FE ;

Diessel, E ;

Brezger, M ;

Sieper, J ;

Felsenberg, D ;

Braun, J .

OSTEOPOROSIS INTERNATIONAL, 2000, 11 (05) :400-407

[4]

Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]

[5] Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α [J].

Allali, F ;

Breban, M ;

Porcher, R ;

Maillefert, JF ;

Dougados, M ;

Roux, C .

ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (04) :347-349

[6] Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency [J].

Ammann, P ;

Rizzoli, R ;

Bonjour, JP ;

Bourrin, S ;

Meyer, JM ;

Vassalli, P ;

Garcia, I .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1699-1703

[7] BIOLOGICAL PROPERTIES OF RECOMBINANT HUMAN MONOCYTE-DERIVED INTERLEUKIN-1 RECEPTOR ANTAGONIST [J].

AREND, WP ;

WELGUS, HG ;

THOMPSON, RC ;

EISENBERG, SP .

JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (05) :1694-1697

[8] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[9] CTLA-4 directly inhibits osteoclast formation [J].

Axmann, R. ;

Herman, S. ;

Zaiss, M. ;

Franz, S. ;

Polzer, K. ;

Zwerina, J. ;

Herrmann, M. ;

Smolen, J. ;

Schett, G. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1603-1609

[10] Lack of association between interleukin-1 receptor antagonist protein gene polymorphism and bone mineral density in Hungarian postmenopausal women [J].

Bajnok, É ;

Takács, I ;

Vargha, P ;

Speer, G ;

Nagy, Z ;

Lakatos, P .

BONE, 2000, 27 (04) :559-562

← 1 2 3 4 5 6 7 8 9 10 →